KUALA LUMPUR: Amway (Malaysia) Holdings Bhd will continue to focus on the health and wellbeing space as market conditions remain challenging due to cautious consumer spending.
In a filing with Bursa Malaysia, the group said it will emphasise science-backed solutions that support healthy ageing and long-term wellbeing, while adapting its business model to address evolving consumer preferences and market dynamics.
Additionally, the group will also undertake disciplined investments aimed at strengthening sales capabilities, supporting product innovation and enhancing its digital and physical infrastructure.
"The cautious consumer environment is expected to continue weighing on the group’s sales for the remainder of the year. However, as a result of prudent investments and product price adjustments, profitability is expected to stabilise," said the group.
In the third quarter ended Sept 30, 2026, Amway's net profit fell to RM12.07mil from RM14.62mil in the same quarter in 2025, underpinned by lower revenue of RM258.28mil as compared to RM275.55mil previously.
It said the decline was mainly attributable to a
higher comparative base resulting from the cellular health product launch in September 2025.
The group also put in a weaker year-to-date performance with net profit in 9MFY26 falling to RM26.49mil from RM30.27mil in 9MFY25, and revenue sliding to RM792.07mil from RM836.54mil in the comparative period.
The group attributed the year-to-date decline to continued softness in consumer demand.
The board declared a third interim dividend of five sen per share, with ex date on Dec 3, 2026, and payment on Dec 18, 2026.
